Truist Financial Issues Pessimistic Forecast for Astrana Health (NASDAQ:ASTH) Stock Price

Astrana Health (NASDAQ:ASTH) had its price objective lowered by Truist Financial from $50.00 to $46.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price objective indicates a potential upside of 48.84% from the stock’s previous close.

A number of other brokerages also recently weighed in on ASTH. Bank of America decreased their price target on Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Macquarie upgraded Astrana Health to a “hold” rating in a report on Monday, December 16th. Robert W. Baird decreased their price target on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a report on Monday, March 3rd. Finally, Stifel Nicolaus decreased their price target on Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, February 20th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.17.

Astrana Health Trading Up 1.0 %

NASDAQ ASTH traded up $0.31 on Tuesday, reaching $30.91. The company had a trading volume of 16,111 shares, compared to its average volume of 248,699. The firm has a market cap of $1.74 billion, a price-to-earnings ratio of 23.77, a P/E/G ratio of 1.37 and a beta of 1.30. Astrana Health has a fifty-two week low of $23.12 and a fifty-two week high of $63.20. The business has a 50 day moving average of $33.95 and a two-hundred day moving average of $42.95. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91.

Astrana Health (NASDAQ:ASTH) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The company had revenue of $665.21 million during the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. Analysts forecast that Astrana Health will post 1.15 EPS for the current year.

Institutional Trading of Astrana Health

Several large investors have recently made changes to their positions in ASTH. Handelsbanken Fonder AB lifted its position in Astrana Health by 4.7% in the 4th quarter. Handelsbanken Fonder AB now owns 8,900 shares of the company’s stock valued at $281,000 after acquiring an additional 400 shares in the last quarter. Quarry LP lifted its position in Astrana Health by 35.5% in the 4th quarter. Quarry LP now owns 1,799 shares of the company’s stock valued at $57,000 after acquiring an additional 471 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Astrana Health by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,505 shares of the company’s stock valued at $773,000 after acquiring an additional 915 shares in the last quarter. Swiss National Bank lifted its position in Astrana Health by 1.1% in the 4th quarter. Swiss National Bank now owns 88,444 shares of the company’s stock valued at $2,789,000 after acquiring an additional 1,000 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its position in Astrana Health by 4.7% in the 4th quarter. MetLife Investment Management LLC now owns 26,284 shares of the company’s stock valued at $829,000 after acquiring an additional 1,173 shares in the last quarter. 52.77% of the stock is currently owned by institutional investors and hedge funds.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.